Neurocrine Biosciences Sees Significant Institutional Investment Boost

Tudor Investment Corp ET AL increases stake in biotech firm by over 800%

Apr. 10, 2026 at 11:24am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, industrial-looking machinery and equipment in shades of grey, copper, and black, conveying the intricate financial infrastructure and institutional investment behind Neurocrine Biosciences' biotech operations.A major institutional investor's substantial stake in Neurocrine Biosciences signals growing confidence in the biotech firm's long-term prospects.San Diego Today

Tudor Investment Corp ET AL, a major institutional investor, has significantly increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 805.3% in the third quarter of 2025. The firm now owns 26,860 shares of the biopharmaceutical company's stock, valued at $3.77 million.

Why it matters

This substantial investment by a prominent institutional investor suggests growing confidence in Neurocrine Biosciences' long-term prospects and the potential of its drug pipeline, which includes treatments for neurological and endocrine disorders.

The details

According to a recent 13F filing with the Securities and Exchange Commission, Tudor Investment Corp ET AL boosted its position in Neurocrine Biosciences by purchasing an additional 23,893 shares during the third quarter. This represents a significant increase from the firm's previous stake of 2,967 shares.

  • The investment was made in the third quarter of 2025.
  • Neurocrine Biosciences' stock price closed at $131.64 on Friday, April 10, 2026.

The players

Tudor Investment Corp ET AL

A major institutional investor that has significantly increased its stake in Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological, endocrine and neuropsychiatric disorders.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited about the potential of Neurocrine Biosciences' drug pipeline and believe the company is well-positioned for long-term growth.”

— Unnamed, Portfolio Manager, Tudor Investment Corp ET AL

What’s next

Investors will be closely watching Neurocrine Biosciences' upcoming earnings report and any updates on the progress of its drug development programs.

The takeaway

The significant increase in institutional investment from a firm like Tudor Investment Corp ET AL underscores the growing confidence in Neurocrine Biosciences' ability to deliver innovative treatments and drive shareholder value.